featured-image

DWithers This article was updated at 220p ET with a statement from GSK. A Chicago jury on Thursday denied a woman's claim that the heartburn drug Zantac (ranitidine), originally marketed by GSK ( NYSE: GSK ), was responsible for her developing colon cancer. The verdict is the first to be reached among the thousands of lawsuits facing GSK and other drugmakers alleging that ranitidine can cause different types of cancer.

The plaintiff had alleged that taking Zantac and its generic versions from 1995 to 2014 led to her colon cancer, Reuters reported. The Chicago lawsuit and others like it argue that ranitidine can sometimes contain the carcinogen NDMA. Ranitidine was pulled from the market in 2020.



In a statement , GSK said, "This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine." The plaintiff's attorneys were seeking $640M for suffering as well as punitive damages. More on Zantac lawsuits GSK faces another Zantac whistleblower lawsuit Pfizer agrees to pay up to $250M to settle Zantac cancer lawsuits - report Sanofi reportedly settles 4K Zantac cases for $100M GSK settles another Zantac lawsuit in California.

Back to Health Page